TARIS is advancing TAR-200 for the treatment of muscle-invasive bladder cancer (MIBC). This system continuously administers the chemotherapeutic agent, gemcitabine, for multiple weeks. TAR-200 has the potential to harness both cytotoxic and immuno-oncologic activity, without meaningful systemic drug exposure. This may yield a powerful new therapy while mitigating the potential for systemic side-effects.
A large portion of MIBC patients do not receive potentially curative therapy (radical cystectomy or curative radiotherapy). These patients have no meaningful therapeutic options, suffer from substantial symptom burden, and often quickly succumb to their disease. TAR-200 has the unique potential to markedly improve survival and overall outcomes for these profoundly underserved patients. TARIS is committed to rapidly advancing TAR-200 for this indication.